Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients

被引:5
|
作者
Long, Lu [1 ,2 ]
Shen, Tao [1 ,2 ]
Gao, Jian [1 ,2 ]
Duan, Zhaojun [1 ,2 ]
Liang, Hua [3 ]
Lu, Fengmin [1 ,2 ]
机构
[1] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100191, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Ctr Infect Dis, Beijing 100191, Peoples R China
[3] China CDC, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Ctr AIDS STD Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 100026, Peoples R China
来源
BMC INFECTIOUS DISEASES | 2014年 / 14卷
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
CD4+T-cell counts; Coinfection; HCV-coreAg; HCV-RNA; HCV/HIV-1; Ratio; HEPATITIS-C-VIRUS; CLINICAL UTILITY; HIV-INFECTION; IMMUNE ACTIVATION; LIVER-DISEASE; ASSAY; CHINA; HEMODIALYSIS; PERFORMANCE; MARKER;
D O I
10.1186/s12879-014-0577-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The measurement of hepatitis C virus core antigen (HCV-coreAg) has been shown to be an indicator of active HCV infection. The aim of the present study was 1) to investigate the stability and effectiveness of HCV-coreAg and HCV-RNA quantification in HCV infection with or without HIV-1 coinfection, 2) to explore the association between the HCV-coreAg/HCV-RNA (Ag/RNA) ratio and the immune status in chronic HCV/HIV-1-coinfected patients. Methods: A longitudinal investigation comprised of 227 HCV-monoinfected (n = 129) and HCV/HIV-1-coinfected (n = 98) patients was initiated in August 2009, and 139 (73 with HCV monoinfection and 66 with HCV/HIV-1 coinfection) were followed up in August 2012. Both HCV core antigen and HCV RNA quantification were determined on this cryopreserved plasma. HCV core antigen and HCV RNA quantification were performed subsequently. In addition, an in vitro experiment investigating the possibility of degradation of HCV components (core antigen and RNA) were conducted. Results: Significant and stable correlations (p < 0.001) were observed both in chronic HCV-monoinfected and HCV/HIV-1-coinfected patients over the 3-year observation. Coinfected patients with immunocompromised condition had a significantly higher (p < 0.05) Ag/RNA ratios than those patients with immunocompetent condition both at two time points (2009 and 2012). Moreover, the Ag/RNA ratios were negatively correlated with CD4+ T-cell counts (p < 0.001). An in vitro experiment investigated the possibility of the slower degradation of HCV particles under HIV-related immunocompromised condition was conducted and the data demonstrated that the Ag/RNA ratios were significantly higher in HIV-1-positive plasma than in healthy plasma (p = 0.005) in this study. Conclusions: Our longitudinal study indicated that the HCV-coreAg presented comparable dynamics over time as HCV RNA in chronic HCV-infected patients. Meanwhile, the HCV-coreAg/HCV-RNA ratio was closely associated with immune status in HCV/HIV-1-coinfected patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
    Lu Long
    Tao Shen
    Jian Gao
    Zhaojun Duan
    Hua Liang
    Fengmin Lu
    BMC Infectious Diseases, 14
  • [2] HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis
    Mederacke, Ingmar
    Potthoff, Andrej
    Meyer-Olson, Dirk
    Meier, Matthias
    Raupach, Regina
    Manns, Michael P.
    Wedemeyer, Heiner
    Tillmann, Hans Ludger
    JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (02) : 110 - 115
  • [3] HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
    Garbuglia, Anna Rosa
    Monachetti, Alessia
    Galli, Claudio
    Sabatini, Rosella
    Ferreri, Monica Lucia
    Capobianchi, Maria Rosaria
    Bagnarelli, Patrizia
    BMC INFECTIOUS DISEASES, 2014, 14
  • [4] The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
    Xiang, Yu
    Lai, Xiao-fei
    Chen, Pu
    Yang, Yang
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (01)
  • [5] A Higher Correlation of HCV Core Antigen with CD4+T Cell Counts Compared with HCV RNA in HCV/HIV-1 Coinfected Patients
    Shen, Tao
    Chen, Xiangmei
    Zhang, Weidong
    Xi, Yuanlin
    Cao, Guanghua
    Zhi, Yuhong
    Wang, Shuiwang
    Xu, Chunhui
    Wei, Lai
    Lu, Fengmin
    Zhuang, Hui
    PLOS ONE, 2011, 6 (08):
  • [6] Comparison of HCV core antigen and anti-HCV with HCV RNA results
    Buket, Cicioglu Aridogan
    Ayse, Aynali
    Selcuk, Kaya
    Suleyman, Oenal
    Emel, Sesli Cetin
    AFRICAN HEALTH SCIENCES, 2014, 14 (04) : 816 - 820
  • [7] COMPARISON OF HCV RNA AND HCV CORE ANTIGEN IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS
    Karabay, Oguz
    Ogutlu, Aziz
    Ankarali, Handan
    Ozdemir, Fatma
    Karabay, Meltem
    Gozdas, Hasan Tahsin
    ACTA MEDICA MEDITERRANEA, 2014, 30 (05): : 1025 - 1028
  • [8] HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients
    Rockstroh, Jurgen Kurt
    Feld, Jordan J.
    Chevaliez, Stephane
    Cheng, Kevin
    Wedemeyer, Heiner
    Sarrazin, Christoph
    Maasoumy, Benjamin
    Herman, Christine
    Hackett, John, Jr.
    Cohen, Daniel E.
    Dawson, George J.
    Cloherty, Gavin
    Pawlotsky, Jean-Michel
    JOURNAL OF VIROLOGICAL METHODS, 2017, 245 : 14 - 18
  • [9] HCV Core-antigen Assay as an Effective Alternative to HCV RNA Quantification in Patients With Hepatitis C
    Vieira, Raquel
    Caldas, Carlos
    Carvalho, Jose Antonio
    Costa, Eliana
    Magalhaes, Tomas Rodrigues
    Queiroga, Felisbina Luisa
    IN VIVO, 2023, 37 (04): : 1498 - 1503
  • [10] HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia
    Alonso, Roberto
    Perez-Garcia, Felipe
    Lopez-Roa, Paula
    Alcala, Luis
    Rodeno, Pilar
    Bouza, Emilio
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (03): : 175 - 178